Affymetrix and Incyte Genomics Settle All Patent Infringement Litigation
PALO ALTO, Calif. and SANTA CLARA, Calif., Dec 21, 2001 /PRNewswire via COMTEX/ -- Incyte Genomics, Inc. (Nasdaq: INCY chart, msgs), the leading genomics information company and Affymetrix, Inc., (Nasdaq: AFFX chart, msgs) the leader in creating breakthrough tools for the genomic revolution, today announced a comprehensive settlement of all existing infringement litigation between the two companies. The first lawsuit involved several of Affymetrix microarray-related patents (U.S. Patent Nos. 5,445,934, 5,744305, 5,800,992, 5,871,928, 6,040,193). The second lawsuit involved Incyte's RNA amplification patents (U.S. Patent Nos. 5,716,785, 5,891,636). The companies have agreed to cross-licenses under their respective intellectual property portfolios. Financial terms were not disclosed. Affymetrix and Incyte also are investigating possible future commercial agreements between the companies
Source: Incyte Genomics, Inc. |
